These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869 [TBL] [Abstract][Full Text] [Related]
4. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. Castillo-Olivares J; Wells DA; Ferrari M; Chan ACY; Smith P; Nadesalingam A; Paloniemi M; Carnell GW; Ohlendorf L; Cantoni D; Mayora-Neto M; Palmer P; Tonks P; Temperton NJ; Peterhoff D; Neckermann P; Wagner R; Doffinger R; Kempster S; Otter AD; Semper A; Brooks T; Albecka A; James LC; Page M; Schwaeble W; Baxendale H; Heeney JL Front Immunol; 2021; 12():748291. PubMed ID: 34867975 [TBL] [Abstract][Full Text] [Related]
5. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342 [TBL] [Abstract][Full Text] [Related]
6. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693 [TBL] [Abstract][Full Text] [Related]
7. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B Front Immunol; 2021; 12():614436. PubMed ID: 33790892 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. Havervall S; Jernbom Falk A; Klingström J; Ng H; Greilert-Norin N; Gabrielsson L; Salomonsson AC; Isaksson E; Rudberg AS; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Christ W; Olausson M; Hedhammar M; Tegel H; Mangsbo S; Phillipson M; Månberg A; Hober S; Nilsson P; Thålin C PLoS One; 2022; 17(1):e0262169. PubMed ID: 35020778 [TBL] [Abstract][Full Text] [Related]
9. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients. Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Seow J; Graham C; Merrick B; Acors S; Pickering S; Steel KJA; Hemmings O; O'Byrne A; Kouphou N; Galao RP; Betancor G; Wilson HD; Signell AW; Winstone H; Kerridge C; Huettner I; Jimenez-Guardeño JM; Lista MJ; Temperton N; Snell LB; Bisnauthsing K; Moore A; Green A; Martinez L; Stokes B; Honey J; Izquierdo-Barras A; Arbane G; Patel A; Tan MKI; O'Connell L; O'Hara G; MacMahon E; Douthwaite S; Nebbia G; Batra R; Martinez-Nunez R; Shankar-Hari M; Edgeworth JD; Neil SJD; Malim MH; Doores KJ Nat Microbiol; 2020 Dec; 5(12):1598-1607. PubMed ID: 33106674 [TBL] [Abstract][Full Text] [Related]
11. Robust and durable serological response following pediatric SARS-CoV-2 infection. Renk H; Dulovic A; Seidel A; Becker M; Fabricius D; Zernickel M; Junker D; Groß R; Müller J; Hilger A; Bode SFN; Fritsch L; Frieh P; Haddad A; Görne T; Remppis J; Ganzemueller T; Dietz A; Huzly D; Hengel H; Kaier K; Weber S; Jacobsen EM; Kaiser PD; Traenkle B; Rothbauer U; Stich M; Tönshoff B; Hoffmann GF; Müller B; Ludwig C; Jahrsdörfer B; Schrezenmeier H; Peter A; Hörber S; Iftner T; Münch J; Stamminger T; Groß HJ; Wolkewitz M; Engel C; Liu W; Rizzi M; Hahn BH; Henneke P; Franz AR; Debatin KM; Schneiderhan-Marra N; Janda A; Elling R Nat Commun; 2022 Jan; 13(1):128. PubMed ID: 35013206 [TBL] [Abstract][Full Text] [Related]
15. Evolution of antibody immunity to SARS-CoV-2. Gaebler C; Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Tokuyama M; Cho A; Jankovic M; Schaefer-Babajew D; Oliveira TY; Cipolla M; Viant C; Barnes CO; Bram Y; Breton G; Hägglöf T; Mendoza P; Hurley A; Turroja M; Gordon K; Millard KG; Ramos V; Schmidt F; Weisblum Y; Jha D; Tankelevich M; Martinez-Delgado G; Yee J; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Robbiani DF; Zhao Z; Gazumyan A; Schwartz RE; Hatziioannou T; Bjorkman PJ; Mehandru S; Bieniasz PD; Caskey M; Nussenzweig MC Nature; 2021 Mar; 591(7851):639-644. PubMed ID: 33461210 [TBL] [Abstract][Full Text] [Related]
16. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698 [TBL] [Abstract][Full Text] [Related]
17. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Reynolds CJ; Swadling L; Gibbons JM; Pade C; Jensen MP; Diniz MO; Schmidt NM; Butler DK; Amin OE; Bailey SNL; Murray SM; Pieper FP; Taylor S; Jones J; Jones M; Lee WJ; Rosenheim J; Chandran A; Joy G; Di Genova C; Temperton N; Lambourne J; Cutino-Moguel T; Andiapen M; Fontana M; Smit A; Semper A; O'Brien B; Chain B; Brooks T; Manisty C; Treibel T; Moon JC; ; Noursadeghi M; ; Altmann DM; Maini MK; McKnight Á; Boyton RJ Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33361161 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Yang Y; Yang M; Peng Y; Liang Y; Wei J; Xing L; Guo L; Li X; Li J; Wang J; Li M; Xu Z; Zhang M; Wang F; Shi Y; Yuan J; Liu Y Nat Microbiol; 2022 Mar; 7(3):423-433. PubMed ID: 35132197 [TBL] [Abstract][Full Text] [Related]
19. Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection. Siracusano G; Brombin C; Pastori C; Cugnata F; Noviello M; Tassi E; Princi D; Cantoni D; Malnati MS; Maugeri N; Bozzi C; Saretto G; Clementi N; Mancini N; Uberti-Foppa C; Temperton N; Bonini C; Di Serio C; Lopalco L Front Immunol; 2021; 12():772239. PubMed ID: 34804064 [TBL] [Abstract][Full Text] [Related]
20. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]